Table 2.
The baseline characteristics of glyburide users and glipizide users from five Sentinel data partners with high dimensional propensity score models converged and completed without errors.
| Covariates | Unmatched | Matched on predefined covariates | Matched on hdPS only | Matched on predefined covariates & hdPS |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| New Users a | Glyburide (N=139,11 6) |
Glipizide (N=181,91 2) |
Standardized difference |
Glyburide (N=120,33 6) |
Glipizide (N=120,33 6) |
Standardized difference | Glyburide (N=116,93 2) |
Glipizide (N=116,93 2) |
Standardized difference | Glyburide (N=116,64 1) |
Glipizide (N=116,64 1) |
Standardized difference |
| Gender (Female) | 69,491 | 75,873 | 0.165 | 52,058 | 53,888 | −0.031 | 48,028 | 47,968 | 0.001 | 47,931 | 47,733 | 0.003 |
| (50.0%) | (41.7%) | (43.3%) | (44.8%) | (41.1%) | (41.0%) | (41.1%) | (40.9%) | |||||
| Mean age (SD) | 52.8 | 57.0 | −0.311 | 55.5 | 55.2 | 0.021 | 56.2 | 56.2 | 0.000 | 56.2 (12.4) | 56.2 | 0.003 |
| (14.1) | (12.5) | (12.9) | (12.4) | (12.4) | (12.4) | (12.4) | ||||||
| Recorded history of | ||||||||||||
| Chronic Kidney | 4,704 | 11,470 | −0.136 | 4,648 | 5,483 | −0.035 | 4,604 | 5,402 | −0.034 | 4,605 | 4,677 | −0.003 |
| Disease | (3.4%) | (6.3%) | (3.9%) | (4.6%) | (3.9%) | (4.6%) | (3.9%) | (4.0%) | ||||
| Serious | 2,555 | 4,367 | −0.039 | 2,465 | 2,547 | −0.005 | 2,446 | 2,470 | −0.001 | 2,438 | 2,456 | −0.001 |
| Hypoglycemia | (1.8%) | (2.4%) | (2.0%) | (2.1%) | (2.1%) | (2.1%) | (2.1%) | (2.1%) | ||||
| Insulin | 8,552 | 14,669 | −0.075 | 8,272 | 8,427 | −0.005 | 8,095 | 8,736 | −0.021 | 8,107 | 7,964 | 0.005 |
| (6.1%) | (8.1%) | (6.9%) | (7.0%) | (6.9%) | (7.5%) | (7.0%) | (6.8%) | |||||
| Metformin | 44,603 | 79,171 | −0.236 | 43,977 | 45,16, | −0.020 | 42,705 | 49,924 | −0.126 | 42,794 | 42,656 | 0.002 |
| (32.1%) | (43.5%) | (36.5%) | (37.5%) | (36.5%) | (42.7%) | (36.7%) | (36.6%) | |||||
| Other | 22,311 | 39,383 | −0.144 | 22,137 | 22,791 | −0.014 | 22,098 | 24,727 | −0.056 | 22,121 | 22,171 | −0.001 |
| antidiabetic drugs | (16.0%) | (21.6%) | (18.4%) | (18.9%) | (18.9%) | (21.1%) | (19.0%) | (19.0%) | ||||
| Combined | 0.3 | 0.4 | −0.103 | 0.3 | 0.4 | −0.040 | 0.3 | 0.3 | 0.002 | 0.3 | 0.3 | 0.000 |
| Charlson/Elixhauser comorbidity | (1.5) | (1.8) | (1.5) | (1.6) | (1.6) | (1.6) | (1.6) | (1.6) | ||||
| score (SD) | ||||||||||||
| Health Service Utilization | ||||||||||||
| Intensity | ||||||||||||
| Number of | 4.9 | 5.7 | −0.194 | 5.1 | 5.3 | −0.031 | 5.1 | 5.4 | −0.060 | 5.1 | 5.1 | 0.000 |
| unique generic | (4.1) | (4.5) | (4.3) | (4.3) | (4.3) | (4.2) | (4.3) | (4.2) | ||||
| drugs dispensed (SD) | ||||||||||||
| Number of | 11.8 | 14.5 | −0.201 | 12.6 | 13.0 | −0.030 | 12.7 | 13.3 | −0.045 | 12.7 | 12.7 | 0.001 |
| dispensed | (12.6) | (14.1) | (13.0) | (13.3) | (13.1) | (13.0) | (13.1) | (13.0) | ||||
| prescriptions (SD) | ||||||||||||
| Number of | 0.1 | 0.2 | −0.125 | 0.1 | 0.1 | 0.000 | 0.1 | 0.1 | 0.000 | 0.1 | 0.1 | 0.000 |
| inpatient hospital | (0.5) | (0.5) | (0.5) | (0.5) | (0.5) | (0.5) | (0.5) | (0.5) | ||||
| encounters (SD) | ||||||||||||
| Number of non- | 0.1 | 0.1 | −0.055 | 0.1 | 0.1 | 0.000 | 0.1 | 0.1 | 0.001 | 0.1 | 0.1 | −0.001 |
| acute institutional | (1 0) | (1 2) | (1 0) | (1 0) | (1 1) | (1 1) | (1 1) | (1 1) | ||||
| encounters (SD) | ||||||||||||
| Number of | 0.3 | 0.3 | 0.000 | 0.3 | 0.3 | 0.000 | 0.3 | 0.3 | 0.000 | 0.3 | 0.3 | 0.000 |
| emergency room | (0.7) | (0.9) | (0.8) | (0.8) | (0.7) | (0.8) | (0.7) | (0.7) | ||||
| encounters (SD) | ||||||||||||
| Number of | 6.6 | 6.5 | 0.014 | 6.1 | 6.4 | −0.037 | 5.9 | 6.0 | −0.016 | 5.9 | 5.9 | 0.000 |
| ambulatory | (7.6) | (8.4) | (7.3) | (8.8) | (7.5) | (7.6) | (7.5) | (7.6) | ||||
| encounters (SD) | ||||||||||||
| Number of other | 1.5 | 1.4 | 0.036 | 1.2 | 1.3 | −0.032 | 1.2 | 1.2 | 0.004 | 1.2 | 1.2 | 0.000 |
| ambulatory | (3.2) | (3.4) | (2.9) | (3.4) | (3.0) | (3.0) | (2.9) | (3.0) | ||||
| encounters (SD)b | ||||||||||||
hdPS – High dimensional propensity score; SD – Standard deviation.
a
Please note, one Data Partner removed a small number of users that moved to administrative services only plans. Information from these users is included in Tables 1 and 2, but removed from subsequent tables.
b
Other ambulatory encounters included telemedicine and email consults, etc.